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Prescription cost-containment measures are increasing in many European countries and, as more inhaler
devices become available, there may be pressure to switch patients from reference inhaled medication to
cheaper generic inhaled drugs. Indeed, in some countries, such a substitution is mandated by current
regulations, and patients who do not accept the substitution have to pay the difference in cost. Generic
inhaled drugs are therapeutically equivalent to original branded options but may differ in their formu-
lation and inhalation device. This new situation raises questions about the potential impact of switching
from branded to generic inhaled medications in patients with asthma or chronic obstructive pulmonary
disease (COPD), with or without their consent, in countries where this is permitted. Acquisition cost
savings from a substitution could be offset by costs related to deterioration in asthma control or wors-
ening in COPD outcomes if the patient is unable or unwilling to use the inhaler device properly. Non-
adherence to therapy and incorrect inhaler usage are recognised as major factors in uncontrolled
asthma and worsening of COPD outcomes. Switching patients to a different inhaler device may exac-
erbate these problems, particularly in patients who disagree to switch. Where switching is permitted or
mandatory, it is crucial that the reason for switching has been properly explained to the patient and
adequate instruction for operating correctly the inhaler have clearly been provided.
© 2015 Elsevier Ltd. All rights reserved.Contents
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with the initial branded treatment in COPD is low, with a sub-
stantial proportion of patients changing therapy (switch or add-on
therapy). Whether these changes in dispensing patterns are
physician-instigated or patient-driven is not clear, neither are fully
understood the factors driving the changes but, among them, de-
vice acceptability must be considered [1].
Several European countries are experiencing an explosion of
new drugs and inhaler devices, either pressurized metered dose
inhalers (pMDIs) or dry powder inhalers devices (DPIs), being
licensed for patients with asthma or chronic obstructive pulmonary
disease (COPD). Some pharma companies have invested much
money in research and development of unique new inhaler device
platforms for delivering different inhaled drugs. Examples of these
new delivery system platforms are the Respimat® soft mist inhaler
which is the inhaler of choice for administration of the long-acting
antimuscarinic (LAMA) drug Tiotropium and the long-acting beta
adrenergic bronchodilator (LABA) drug Olodaterol; the Ellipta® DPI
for administration of the LAMA drug Umeclidinium, the LABA drug
Vilanterol, and the corticosteroid Fluticasone Furoate; the Genuair®
DPI for administration of LAMA drug Aclidinium and LABA drug
Formoterol, the Breezhaler® DPI for administration of the LABA
drug Indacaterol and the LABA drug Glycopirronium; the
Nexthaler® DPI for administration of the fixed combination of the
corticosteroid Beclomethasone Dipropionate with the LABA For-
moterol; the Spiromax® DPI for the administration of the fixed
combination of the LABA drug Formoterol with the corticosteroid
Busonide, and the fixed combination of the LABA drug Salmeterol
with the corticosteroid Fluticasone Propionate. In addition to these
branded inhaled medications, the expiration of the patent protec-
tion covering the established inhaled bronchodilators, corticoste-
roids, and their fixed combinations has contributed to the
development of several “generic” inhaled drugs that are bio-
equivalent [2] to the original reference listed inhaled medications.
Generic inhaled medications have the same chemical structure as
branded medications but they are not necessarily delivered by the•Assessment
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Fig. 1. Treatment algorithm indevices often protected by ongoing patents. Rather generics are
delivered by relatively low cost inhalation devices that can vary
markedly in design, drug delivery and method of operation than
devices of the original branded drugs. The substantial differences
that exist in the design of inhaler products makes very difficult to
develop generic versions of inhaler products that are inter-
changeable and substitutable with the originator products. We will
face in the next years with newly engineered devices, with the
availability of more drugs delivered by the same device but also
with the pressure of prescribing cost-containment measures. The
last are increasing in many countries and, as more inhalers become
available, it is feasible that extending the use of generics is
considered an important element to achieve substantial savings
theoretically at no detrimental to patient care. Thus, switching
patients from reference inhaled drugs to lower-cost “generic”
inhaled ones may represent an opportunity for reducing cost of
drug treatments in asthma and COPD [3,4].
The present document has been prepared by a working group of
Italian Society of Respiratory Medicine (SIMeR) and Italian Society
of Allergy, Asthma and Clinical Immunology (SIAACI) with the aim
to review the current regulations on generic substitution of mar-
keted reference inhaled medications in Europe. We also question if
switching patients from reference to generic inhaled drugs may
have potential deleterious effects on asthma control and COPD
outcomes. Description of current regulatory requirements associ-
ated with the development and submission of dossiers for inhaled
medications is outside the scope of this article; excellent de-
scriptions of this aspect can be found in the literature [see e.g. [5e7]
also for further references].
2. Regulatory framework for orally inhaled medications
When developing a new therapeutically active moiety, the
applicant has to provide evidence for the safety, efficacy and quality
of the new therapeutically active moiety, as well as the drug
product containing the therapeutically active moiety. In case the
therapeutically active moiety is known and marketed drug productr
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quality of the new generic product with reference to existing safety
and efficacy data when submitting a generic of the product.
Although bioequivalence principles have firmly been defined [5], at
present there is no international consensus on many of the details
regarding the requirements for the design, conduct and evaluation
of bioequivalence studies. Consequently, each regulatory authority
[see e. g. 8e10] has issued its own corresponding guidelines.
According to the European directive [11], a generic product must
contain the same active substance in the same amount as the
reference product and demonstrate its therapeutic equivalence,
which is defined as sufficiently comparable efficacy and safety
profile of the test and reference products so that a clinically relevant
difference between products can be reliably excluded [8]. It is re-
sponsibility of regulatory authorities to ensure that a generic
product is equivalent to the originator product in all important re-
spects, and to assure patients and prescribers that there is no sig-
nificant difference between the two products in the clinic [11]. The
European Medical Agency (EMA) guideline provides the possibility
to consider approving a generic version of an inhaler product based
on in vitro assessment in case the product meets all the stringent
criteria set forth in the guideline that leads to the assumption that
the generic version of theproduct is therapeutic interchangeable [8].
In case the in vitro comparability is not given, lung deposition tests
are required that might have to be complemented by pharmaco-
dynamics and eventually clinical studies. Even so demonstrating
equivalent bioavailability at the site(s) of action for orally inhaled
products has been proposed as a suitable way to demonstrate
essential similarity, the EMAmade clear that “orally inhaled products
are definitively not ‘generics’ but hybrids” and that ‘‘simple bridging to
the bioequivalence model is mostly not sufficient.” [8].
In the US, orally inhaled drug products are considered combi-
nations products and are defined by the Food and Drug Adminis-
tration (FDA) as “therapeutic and diagnostic products that combine
drugs, devices, and/or biological products”, in which the device, the
formulation and the patient interact in a complexmanner to deliver
a specific dose of fine drug particles to the different regions in the
lung [9,10]. Moreover, each device differs from the othermaking the
development of a generic product that is therapeutically inter-
changeable very challenging [10]. The FDA requires generic manu-
facturers to demonstrate equivalent delivery to the lungs, equivalent
systemic exposure with the generic product and comparability of
the pMDI or the DPI they propose to use to that of the branded
product [10]. However, there is no consensus on theprotocols for the
necessary studies [12]. In addition, the excipients in the generic
product must be qualitatively and quantitatively the same as those
in the reference product. Due to the difficulties in demonstrating
bioequivalence between generic and reference inhaled drugs, FDA
received few applications for generics, even though many of the
older pMDI products are on themarketwithout patent or exclusivity
protection. The FDA recognises the challenges that these re-
quirements present and is currently working with manufacturers,
regulatory bodies and academia to find solutions to them [6,12].
3. Switching regulations and physicians' opinion on inhaler
substitution in Europe
In Europe, regulations on generic substitution of marketed
drugs vary from country to country [4]. In some countries (i. e.
Germany and Finland), substitution of branded inhaler medications
is mandated by current regulations, while in others (i. e. the UK and
the Netherlands) substitution is permitted if generic names are
used on the prescription. To ensure continuity of use with a
particular device, the phrase ‘medical necessity’ must be used on
the prescription. Interestingly, the Lung Alliance Netherlands hasbeen working with healthcare insurers to develop guidelines that
specifically address the conditions under which switching to the
insurer's preferred (lower cost) inhaler device might be acceptable;
at the present, more than 80 inhalers currently available in the
Netherlands can be considered interchangeable [13]. In Italy,
generic inhalers are available and pharmacists may switch respi-
ratory patients from one combination of drug and inhaler device to
a generic unless the prescription specifies that the patient must not
be switched. Patients who do not accept the substitution of a
branded product with a generic have to pay the difference in cost.
In Spain regulatory and expert bodies advocate for the safety of
patients and their ability to have a voice in treatment decisions,
especially in the case of patients who are established on a long-
term treatment regime. At variance with the above mentioned
countries, in France there are no generics for inhaled products that
can be substituted for branded products, although some pMDIs
could be considered interchangeable.
A survey of healthcare professionals in the UK [14] found that
the vast majority of themwere concerned about potential problems
arising from prescriptions that do not specify the inhaler to be
dispensed, and 46% of the interviewed physicians were aware of
actual incidents in which patients received unfamiliar inhaler
including patient confusion, ineffective inhaler technique and the
need to reissue prescriptions. In another survey [15] conducted at
the primary and secondary care level in Germany, the Netherlands
and UK one third of the physicians interviewed considered the
inhaler before considering the chemical entity within a class of
treatments and over half the respondents reported problems with
the inhaler as one of the main reasons for switching inhaled ther-
apy. A Delphi process was undertaken with four leaders in respi-
ratory medicine to identify important themes relating to
interchangeability of DPIs [15]. These themeswere developed into a
structured questionnaire to use with the respondents in France,
Germany and UK. Only 9% of the physician interviewed thought
that DPIs were interchangeable while the remaining considered
these inhalers not interchangeable [15]. In addition, over 90% of the
physicians thought that interchangeability of DPIs would have a
negative impact on patients adherence and inhaler handling and on
willingness to use the inhaler if the patients was not involved in the
choice of the device. Furthermore, about 80% of physicians thought
that substitution of a patient's regular DPI with another could have
a negative impact on asthma control [15]. The majority of physi-
cians were opposed to substitution of one DPI for another device if
the pharmacist does not consult the patient and/or the physician.
Taken together, the results of these surveys indicated that health-
care professionals perceive inhaler devices as different and not
interchangeable, with physicians opposed to substitution of one
device by another without consultation with the patient. In addi-
tion, healthcare professionals believe patients involvement in the
inhaler choice to be essential for adherence to therapy.
4. Real-life experience
The pMDIs and DPIs are the most frequently prescribed inhaler
devices in Europe [16]; they differ in their efficiency of drug de-
livery to the lower respiratory tract, depending on the design of the
device, its internal resistance, the formulation of the medication, its
particle size, the velocity of the produced aerosol plume, and how
easily the patients can use the device. The efficiency of drug de-
livery may also be influenced by patients' preference, which, in
turn, affects patients' adherence to treatment and, indeed, the
subsequent long-term control of the disease. DPIs in particular can
vary markedly in design and method of operation [17] and this
could lead to different handling errors in a real-life context [18].
When long-term users of branded inhaled drugs are dispensed
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familiar with the new device and could become aware of a change
in taste/sensation [19]. This may reduce their confidence in the
efficacy of the generic drug, increasing the risk of poor compliance
and possibly loss of asthma control [20]. There was an example of
this in 2005, when New Zealand's medication funding authority
removed the subsidy on the branded salbutamol pMDI (Ventolin®),
intending to gradually replace it with the cheaper generic, the
Salamol® pMDI [21]. Bioequivalence between Ventolin and Salamol
pMDIs has been demonstrated in patients with asthma [21].
However, since its introduction to New Zealand anecdotal reports
[22] of decreased therapeutic effect, inhaler blockage and un-
pleasant taste were reported. Reti et al. [23] found that half of those
patients converted to the Salamol pMDI withdrew prematurely due
to ineffectiveness and that, in those who continued to use Salamol,
nearly all had worse asthma stability. In contrast, Chang et al. [24]
found no difference in the efficacy of Salamol and Ventolin pMDIs
in relieving bronchoconstriction. Differences in the patient popu-
lation, study design and methodology used may account for the
conflicting results. However, it should be noted that Chang et al.
[24] administered both salbutamol formulations using pMDIs in
conjunction with spacers, thus affecting drug deposition and
consequently the effectiveness of both preparations. An earlier
study showed that failure to shake the canister before each inha-
lation halved the systemic availability of budesonide from a pMDI
compared with that from the pMDI used with a spacer [25], con-
firming that suboptimal usage can have a profound effect on drug
delivery from a pMDI and that use of a spacer can mitigate this
variability [25].
5. Switching without consultation
Successful management of asthma and COPD is dependent on a
number of factors including correct inhaler use [26]. Current
asthma [27] and COPD [28] guidelines emphasise the importance of
training patients how to use their inhalers correctly, and report that
medications are not interchangeable on a ‘mcg’ or ‘per puff’ basis
because newer delivery devices may deliver an higher therapeutic
dose to the lungs. All guidelines and recommendations state that,
whatever device is selected, patients should be instructed in its use
and undergo regular checking of inhaler technique [29,30]. Patients
are more likely to achieve better asthma control and COPD out-
comes as a result of successful dose delivery when they become
familiar with a particular device. However, guidelines provide no
guidance on how inhaler technique training would be provided
when a patient is switched from a branded drug to a generic
alternative, particularly if disagree with the switching (“non-con-
sent switching”). Non-consented switch is defined as the substi-
tution of a delivery device (and medication) without prior approval
or knowledge by the patient. This means that patients do not
receive any counselling from their healthcare provider about the
new medication and device, which may result in poor inhalation
technique and lead to loss of disease control [31]. Concerns
regarding this phenomenon were identified in the US, where
former New York City Public Advocate, Mark Green, has been highly
critical of Pharmacy Benefit Managers in Health Management Or-
ganisations switching patients' medication for purely financial
reasons [32]. Moreover, Lipton et al. [33] also reported how Phar-
macy Benefit Managers exert their influence to change prescribing
decisions on cost grounds. Thomas et al. [31] retrospectively eval-
uated the impact on asthma control of steroid inhaler switching
without an accompanying visit or consultation in the UK. Of note,
over half of device switches were from DPIs to pMDIs. Compared
with matched controls, patients whose steroid inhaler was
switched were significantly more likely to experience unsuccessfulasthma treatment [31]. These results were confirmedmore recently
by Doyle et al. [19] who showed that switching asthma patients'
inhalers without their consent may diminish the self-control
associated with good asthma management, leave the doc-
torepatient relationship damaged, increase resource utilisation,
and waste medication. It is therefore possible that non-consent
switch may not result in cost savings, because of increases in
clinic visits for education and support and negative impacts on
asthma control, resulting in higher short and long-term healthcare
costs. Patient education and involvement in treatment decisions
can improve adherence to therapy [17] but adherence is likely to
decline in patients who have treatment switched without consul-
tation [31,32]. Non-compliance rates already range from 16 to 50%
among patients with asthma and COPD and this contributes to the
morbidity, mortality and associated costs of these conditions
[31,32]. Increasing the risk of poor adherence by switching inhalers
without consultation is likely to add to these problems. In the case
of switching, it is crucial that the reason for the switch has been
properly explained to the patient and instructions for operating the
device correctly have been clearly demonstrated; a routinely
monitoring of inhaler technique at each visit is also mandatory.
6. Recommendations of SIMER and SIAAC
 Over the next few years it is expected that a number of new
branded inhaled drugs as well as the generics of expired
patented medicines will become available.
 The increasing range of inhaler devices represents an opportu-
nity for physicians and pharmacists to optimise inhalation
therapy and technique.
 Switching inhaler devices is recommended only as part of a
concordant asthma or COPD review where inhaler technique is
assessed and patient agreement with the switching is obtained.
 Prescription of generic inhaled drugs is rightly being encour-
aged to reduce expenditure, particularly at the primary care
level, nevertheless appropriate patient's instruction about the
use of the inhaled drugs must be guaranteed.
 Switching patients from one inhaled drugs to another delivered
by a different device may have a negative impact on patient
adherence to the treatment and consequently disease control.
 A patient, who is familiar and stabilized on one type of inhaler,
should not be switched to another device without his/her
involvement and follow-up education.
 Where switching is considered, adequate patient's instruction
on correct inhaler use must be guaranteed.
 Pharmacists are in an excellent position to educate patients
about inhaler technique because they are the last healthcare
professionals seen by patients before an inhaled medication is
used. However, they should guarantee that patients are
dispensed the same inhaler device type for each prescription.
 Simplification of inhalation therapy by prescription of one
instead of multiple inhaler device types must be encouraged.
 Due to the typical time-course of asthma and COPD, switching
from different doses, drugs and, often, inhalers might happen in
daily clinical practice. Therefore, particular attention has to be
deserved to this critical issue.
A practical algorithm on the assessment of asthma control and
COPD outcomes is depicted in Fig. 1. If the patient is unable to
use a particular inhaler correctly despite repeated attempts, a
change in inhaler device should be considered. In the cases
where ongoing, uncontrolled asthma or worsening of COPD
outcomes persists in the face of a correct inhaler technique, then
therapy should be stepped up according to the treatment
guidelines and another appointment scheduled in order to
recheck the symptoms.
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In a national survey conducted on a group of about 2000 in-
dividuals forming a representative sample of the italian population,
iinhaled drugs were recognised as the most common treatment for
asthma and COPD by 65% of the respondents[34]. Most of the re-
spondents tended to attribute positive characteristics to the devices
with regard to safety, reliability, effectiveness, ease of use and
practicality. Approximately 75% of the respondents indicated that
an inhaler device is the best solution for respiratory diseases and
45% believed that inhaler devices could also be useful for other
diseases. Approximately nine patients out of 10 stated that their
physician provided an adequate explanation regarding the inhala-
tion technique [34]. However, a high proportion of patients do not
have the competence to use their device effectively because they
have forgotten what they were taught and no longer apply the
correct technique that theywere trained to use [34]. For this reason,
international guidelines for asthma and COPD management state
that inhalation technique should be assessed regularly and cor-
rected if it is inadequate [34].
For the above mentioned reasons caution should be takenwhen
switching patients from one device to another one. This is partic-
ularly true for DPIs, which differ widely in the way they operate,
their appearance and delivery characteristics [17]. Indeed, patient
preference for different DPIs varies [17], indicating that they are not
all the same from the patient's perspective, although patient pref-
erence for a device does not ensure either improved compliance or
adherence. Thus, inhaler devices should be prescribed with no
switching of device without the involvement of both physician and
patient [35]. Should substitution of a generic for a branded inhaler
be permitted, safeguards are required to ensure that patients
receive adequate training and are willing to use the new device.
Most relevant, the responsibility for such training needs to be
clarified because physicians may not be aware that a prescribed
device has been replaced with a generic drug at the pharmacy [36].
When evaluating the potential cost benefits of switching inhalers,
all relevant costs should be considered, including those arising
from additional consultations, the time required for training and
the management of any subsequent acute events. These costs, plus
the likelihood of repeat consultations and prescriptions among
patients switched to cheaper, less familiar devices, may outweigh
any cost benefits obtained from switching.Conflict of interest
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